Home/Investors/New Enterprise Associates (NEA)

New Enterprise Associates (NEA)

Biotech Investor · 4 portfolio companies

Portfolio

4

Combined Value

$2.7B

Focus Areas

12

Top Stage

Phase 1

Investment Focus

Neuroscience Psychiatry Epilepsy Anxiety Disorders Cognitive Disorders Autoimmune Diseases Neurodegenerative Diseases Ophthalmology Neurology Rare Genetic Diseases Neuromuscular Oncology

Portfolio Companies

Company	Stage	Valuation	Focus
Rapport Therapeutics	Phase 1	$1.3B	Neuroscience, Psychiatry
Annexon	Phase 2	$761.7M	Autoimmune Diseases, Neurodegenerative Diseases
Design Therapeutics	Phase 1	$635.8M	Neurology, Rare Genetic Diseases
Senti Biosciences	Phase 1	$24.2M	Oncology

Frequent Co-Investors

Public market investors1 shared Arch Venture Partners1 shared Third Rock Ventures1 shared Cormorant Asset Management1 shared Johnson & Johnson Innovation – JJDC1 shared Google Ventures (GV)1 shared Satter Investment Management1 shared Westlake Village BioPartners1 shared